- Conditions
- Major Depressive Disorder
- Interventions
- Ziprasidone, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Farmington, Connecticut • Norwich, Connecticut + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 50,417
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants
- Interventions
- BMS-986235 (Treatment A), Rifampin (Treatment B)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
- Interventions
- Lenalidomide, Pembrolizumab
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- cyclophosphamide, etoposide, BCNU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2010
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Tampa, Florida
- Conditions
- Schizophrenia
- Interventions
- Anti-inflammatory Combination Therapy, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- eptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Berkeley, California • Los Angeles, California • Iowa City, Iowa + 1 more
- Conditions
- Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Sacramento, California • Stanford, California + 18 more
- Conditions
- Safety of Short Term Creatine Hydrochloride Dosing
- Interventions
- creatine supplementation
- Dietary Supplement
- Lead sponsor
- Vireo Systems, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Raritan, New Jersey
- Conditions
- Healthy
- Interventions
- Withdraw treatment
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- Canakinumab (investigational), Placebo, Methotrexate (MTX)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
- Conditions
- Macular Edema, Uveitis
- Interventions
- triamcinolone, ranibizumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 100 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Intranasal Ketamine, Intranasal Midazolam
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- Albuterol and budesonide inhalation aerosol
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
- Conditions
- ADHD
- Interventions
- Lisdexamfetamine Dimesylate (LDX)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 36
- States / cities
- Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
- Conditions
- Menorrhagia
- Interventions
- tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 16 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- C-Met Exon 14 Mutation
- Interventions
- Glumetinib
- Drug
- Lead sponsor
- Haihe Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome
- Interventions
- Edetate Calcium Disodium, Multivitamin, Succimer
- Drug · Dietary Supplement
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diet Modification
- Interventions
- Healthy Feeding, Healthy Eating, Reading Readiness
- Behavioral
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Kingston, Rhode Island
- Conditions
- Bone Diseases, Pain
- Interventions
- Denosumab
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Valacyclovir Hydrochloride Tablets 1000 mg, Valtrex® Tablets 1000 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- XTMAB-16
- Drug
- Lead sponsor
- Xentria, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Interventions
- HST-1011, Cemiplimab
- Drug · Biological
- Lead sponsor
- HotSpot Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more